Literature DB >> 36087090

Fifty years of progress in surgical oncology: Melanoma.

Daniel G Coit1, Charlotte E Ariyan1.   

Abstract

This paper outlines the scientific and clinical advances in the treatment of melanoma over the past 50 years. Among the highlights of progress, the dominant themes include evidence-based reduction in the extent and morbidity of surgical procedures in patients with local or regional melanoma without compromising end results, and the introduction of effective systemic therapy, specifically targeted therapy matched to patients based on specific tumor mutations, and immune checkpoint blockade. Management of advanced disease has also changed dramatically, due to improved understanding of the genomic variability of the disease as well as continuing improvements in imaging.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  management; melanoma; surgical oncology

Mesh:

Year:  2022        PMID: 36087090      PMCID: PMC9473298          DOI: 10.1002/jso.27081

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   2.885


  60 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Authors:  Mark B Faries; John F Thompson; Alistair J Cochran; Robert H Andtbacka; Nicola Mozzillo; Jonathan S Zager; Tiina Jahkola; Tawnya L Bowles; Alessandro Testori; Peter D Beitsch; Harald J Hoekstra; Marc Moncrieff; Christian Ingvar; Michel W J M Wouters; Michael S Sabel; Edward A Levine; Doreen Agnese; Michael Henderson; Reinhard Dummer; Carlo R Rossi; Rogerio I Neves; Steven D Trocha; Frances Wright; David R Byrd; Maurice Matter; Eddy Hsueh; Alastair MacKenzie-Ross; Douglas B Johnson; Patrick Terheyden; Adam C Berger; Tara L Huston; Jeffrey D Wayne; B Mark Smithers; Heather B Neuman; Schlomo Schneebaum; Jeffrey E Gershenwald; Charlotte E Ariyan; Darius C Desai; Lisa Jacobs; Kelly M McMasters; Anja Gesierich; Peter Hersey; Steven D Bines; John M Kane; Richard J Barth; Gregory McKinnon; Jeffrey M Farma; Erwin Schultz; Sergi Vidal-Sicart; Richard A Hoefer; James M Lewis; Randall Scheri; Mark C Kelley; Omgo E Nieweg; R Dirk Noyes; Dave S B Hoon; He-Jing Wang; David A Elashoff; Robert M Elashoff
Journal:  N Engl J Med       Date:  2017-06-08       Impact factor: 91.245

3.  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

Authors:  Christian U Blank; Elisa A Rozeman; Lorenzo F Fanchi; Karolina Sikorska; Bart van de Wiel; Pia Kvistborg; Oscar Krijgsman; Marlous van den Braber; Daisy Philips; Annegien Broeks; Johannes V van Thienen; Henk A Mallo; Sandra Adriaansz; Sylvia Ter Meulen; Loes M Pronk; Lindsay G Grijpink-Ongering; Annemarie Bruining; Rachel M Gittelman; Sarah Warren; Harm van Tinteren; Daniel S Peeper; John B A G Haanen; Alexander C J van Akkooi; Ton N Schumacher
Journal:  Nat Med       Date:  2018-10-08       Impact factor: 53.440

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

6.  Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger.

Authors:  C M Balch; S J Soong; A A Bartolucci; M M Urist; C P Karakousis; T J Smith; W J Temple; M I Ross; W R Jewell; M C Mihm; R L Barnhill; H J Wanebo
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

7.  Excision margins in high-risk malignant melanoma.

Authors:  J Meirion Thomas; Julia Newton-Bishop; Roger A'Hern; Gill Coombes; Michael Timmons; Judy Evans; Martin Cook; Jeffery Theaker; Mary Fallowfield; Trevor O'Neill; Wlodek Ruka; Judith M Bliss
Journal:  N Engl J Med       Date:  2004-02-19       Impact factor: 91.245

8.  Results of sentinel lymph node biopsy in patients with thin melanoma.

Authors:  Sandra L Wong; Mary S Brady; Klaus J Busam; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2006-01-30       Impact factor: 5.344

Review 9.  The role of elective lymph node dissection in melanoma: rationale, results, and controversies.

Authors:  C M Balch
Journal:  J Clin Oncol       Date:  1988-01       Impact factor: 44.544

10.  Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.

Authors:  Mark B Faries; Nicola Mozzillo; Mohammed Kashani-Sabet; John F Thompson; Mark C Kelley; Ronald C DeConti; Jeffrey E Lee; James F Huth; Jeffrey Wagner; Angus Dalgleish; Daniel Pertschuk; Christopher Nardo; Stacey Stern; Robert Elashoff; Guy Gammon; Donald L Morton
Journal:  Ann Surg Oncol       Date:  2017-10-10       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.